Original Publication Date: 1 June, 2014
Publication / Source: Immunotherapy
Authors: Robert L Bowman, Johanna A Joyce
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor, accounting for approximately 15% of all primary brain tumors in adults. Despite therapeutic intervention involving surgical resection, ionizing irradiation (IR) and temozolomide, prognosis remains poor, with a median survival of 14.6 months, and a 5-year survival rate of only 3.3% . Due in part to this dismal prognosis, GBM was one of the first diseases to be characterized by The Cancer Genome Atlas.